Form 4: Labcorp EVP vests 6,382 shares; 2,722 withheld

Labcorp’s EVP, Corporate Affairs reported a performance award vesting of 6,382 shares and tax withholding of 2,722 shares at $268.38, leaving 6,238.9467 shares held directly.

Summary

• Sandra D. van der Vaart (EVP, Corporate Affairs) reported transactions in Labcorp Holdings Inc. (LH) common stock on 03/26/2026.
• 6,382 shares were acquired at $0 pursuant to a performance award granted on 02/07/2023 for the three-year period ended 12/31/2025 (Transaction code A).
• 2,722 shares were withheld to satisfy tax obligations at $268.38 per share (Transaction code F).
• Direct beneficial ownership after the transactions is 6,238.9467 shares; no derivative securities were reported.
• Net shares added from the vesting after tax withholding were 3,660.
• Form was signed by Attorney-in-Fact on 03/30/2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as neutral; a routine vesting that modestly increases insider ownership without signaling incremental conviction through open-market activity.

Positives

• Performance award vested, indicating completion of the 2023–2025 performance cycle.
• Executive’s net share ownership increased by 3,660 shares, aligning interests with shareholders.
• No open-market sale occurred; the only reduction was routine tax withholding.

Negatives

• No open-market purchase to signal incremental confidence beyond compensation-related vesting.
• Approximately 43% of vested shares (2,722 of 6,382) were withheld for taxes, reducing net shares added.

Future Outlook

No forward-looking guidance or operational updates; this is a routine equity award vesting and tax withholding event.

Management Comments

• Shares were acquired on March 26, 2026 pursuant to a performance award granted on February 7, 2023 relating to performance during the three-year period ended December 31, 2025.
• Shares were withheld to satisfy tax withholding obligations.

Industry Context

StockSavvy.ai notes this is a standard three-year performance share vesting and net share settlement via tax withholding, common across large-cap healthcare diagnostics companies; it is administrative in nature and not indicative of underlying business performance changes.

Comparison to Industry Standards

• Consistent with peers like Quest Diagnostics (DGX) and Thermo Fisher Scientific (TMO), executives often receive PSUs that vest over three years with tax withholding via net share settlement.
• Open-market insider purchases at peers (e.g., DGX, Hologic (HOLX)) are generally viewed as stronger conviction signals than routine award vestings; this event aligns with routine practice.
• The effective withholding rate (~43% of vested shares) is within typical U.S. executive tax settlement ranges and does not appear unusual relative to sector norms.

Stakeholder Impact

• Minimal dilution relative to gross award due to net share settlement through tax withholding.
• Executive ownership increased by 3,660 shares, modestly aligning interests with shareholders.
• No operational impact disclosed for customers, suppliers, employees, or creditors.

Key Dates

Keywords

Labcorp, LH, Form 4, insider transaction, performance award, PSU vesting, executive compensation, tax withholding, Sandra D. van der Vaart, corporate affairs